SCHEMBL14949341

SCHEMBL14949341

COc1nc(N)cc(Oc2cccc(-c3nnc(Nc4cccc(C)c4)[nH]3)c2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
LMNA P02545 2/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPT P10636 6/20 0.34
TP53 P04637 3/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34
PDGFRA P16234 1/20 0.34
CDK11B P21127 1/20 0.34
FLT3 P36888 1/20 0.34
CDKL2 Q92772 1/20 0.34
CDK8 P49336 1/20 0.33
MAPK1 P28482 2/20 0.33
NFKB1 P19838 1/20 0.32
ADORA2A P29274 1/20 0.32
PIN1 Q13526 1/20 0.32
MAP4K4 O95819 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949696 0.92 PDGFRB (0.41) MEN1KMT2ALMNAALOX15TSHR
SCHEMBL14949356 0.90 CDK8 (0.34) TSHRHSD17B10MAPTTP53PDGFRB
SCHEMBL14949376 0.90 PDGFRB (0.34) MEN1KMT2AMAPTPDGFRBKIT
SCHEMBL14949363 0.90 SYK (0.34) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949316 0.90 RAB9A (0.36) MAPTTP53PDGFRBKITPDGFRA
SCHEMBL14949352 0.90 PDGFRB (0.35) MAPTTP53PDGFRBKITPDGFRA
SCHEMBL14949388 0.89 KIT (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336580 0.88 MAPT (0.47) LMNAMAPTTP53PDGFRBKIT
SCHEMBL14949345 0.86 NPC1 (0.34) MAPTTP53PDGFRBKITPDGFRA
SCHEMBL14949339 0.86 SYK (0.38) MEN1KMT2ALMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 MEN1 2954/4885KMT2A 900/4885LMNA 3696/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 MEN1 2954/4885KMT2A 900/4885LMNA 3696/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 MEN1 2954/4885KMT2A 900/4885LMNA 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.